Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug aims to stop liver failure in MASH cirrhosis

NCT ID NCT07701993

Not yet recruiting Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This phase 3 study tests whether an experimental drug called efimosfermin alfa can prevent serious liver complications in adults with compensated cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug reduces the risk of death, need for liver transplant, or liver decompensation events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called efimosfermin alfa, given as a subcutaneous injection
What this could lead to
If successful, this could become the first approved treatment to prevent liver failure, need for transplant, or death in people with MASH-related cirrhosis.
What could go wrong
This is a large phase 3 trial, but the drug is still experimental. It may not prove effective or could have side effects that outweigh benefits. Results will take years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease Fibrosis metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.